Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

, and hyperglycemia -- common elements of T2DM and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, potentially making DIO-902 a first-in-category treatment.

"We are very encouraged by results of our earlier Phase 2a study that showed a trend toward improved glycemic control, as well as statistically significant reductions in levels of cholesterol and C-reactive protein that suggest DIO-902 could potentially lower the risk of heart disease," said Dr. Bernice Welles, Vice President of Development at DiObex. "DIO-902 could potentially give patients a way to manage their disease with fewer medications and, if ultimately approved, would be a valuable addition to the armamentarium of agents to help patients with type 2 diabetes."

About DIO-902

DIO-902 is a cortisol synthesis inhibitor that is being developed as a therapy for glucose and cholesterol control in patients with T2DM. DIO-902 may also benefit hypercholesterolemia patients who fail to achieve treatment targets on current lipid medications or those who are statin intolerant. DIO-902 increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-beta-hydroxylase

enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-alpha-demethylase, a key enzyme in cholesterol synthesis. DIO-902 is the levdex enantiomer of ketoconazole. Pre-clinical and clinical evidence are supportive that DIO-902 may be safer and more effective than racemic ketoconazole.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hyp
'/>"/>

SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Pharmacovigilance (London, UK ... offering. Understanding PhV today - the ... working in Drug safety. This course ... with pharmacovigilance. New entrants as well as experienced ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... N.J., March 17 Hereditary angioedema (HAE) is ... States each year. Patients with HAE suffer from ... skin, airway, and visceral organs. Left untreated, most ... per month. Chronic therapy with attenuated androgens or ...
... Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March 17 ... appointed David Seth Feldman, MD/PhD, FACC, FAHA to be ... United States, studying the new, third generation DuraHeart(TM) Left ... Francis Pagani, Director of the Heart Transplant and Center ...
Cached Medicine Technology:Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3
(Date:9/4/2015)... Aliso Viejo, CA (PRWEB) , ... September 04, 2015 , ... ... a click of a mouse all within Final Cut Pro X. With TransCel users ... finish. Adjust the frame width, background color, speed method, frame color, inner color, text, ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed an ... , Schmidt National Law Group, a leading firm in mass-tort litigation, has filed ... Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have been ...
(Date:9/4/2015)... ... ... IVF New England, one of the largest and most successful fertility centers in ... women who wish to learn more about their fertility and egg freezing. , Date ... Street, Manchester, NH from 6PM to 7PM , This hip, casual and informative event ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for six seasons, ... In an effort to assist the team, the Jones Agency, a locally owned insurance ... raise funds for the new uniforms. , As is so often the case with ...
(Date:9/4/2015)... ... 2015 , ... A Union County charitable organization will host ... is a non-profit organization dedicated to offering Pilates scholarships to cancer patients to ... recover their mobility, strength, and range of motion following breast cancer surgery. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
... Commence Subsequent Offering Period NEW BRUNSWICK, N.J., Jan. 17 ... that the initial tender offer, through its wholly owned subsidiary, ... stock of Mentor Corporation (NYSE: MNT ) expired ... was not extended.The depositary for the tender offer has advised ...
... 16 Kellogg Company,today announced a voluntary recall ... Crackers and select snack-size packs of Famous Amos(R),Peanut ... Butter,Cookies because the products have the potential to ... in this recall. , ...
... "Company") today has finalized its transaction, initiated in August ... conjunction with this, the reverse stock split (1,000:1) has ... All share certificates may be sent to Computershare ... share certificates, although this is not required. All ...
... The U.S. Department of Labor today announced that it ... under the Energy Employees Occupational Illness Compensation Program Act ... to employees who became ill as a result of ... this program up and running in eight months by ...
... OF PRUSSIA, Pa., Jan. 16 Universal Health Services, ... its Board of Directors voted to pay a cash ... to shareholders of record as of March 2, 2009.Universal ... hospital companies, operating, through its subsidiaries, acute care and ...
... likely to present with worse pathological features at diagnosis ... to Caucasian patients, according to a study conducted by ... are being presented at the 2009 American Society of ... led by Edith Mitchell, M.D., a clinical professor in ...
Cached Medicine News:Health News:Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered 2Health News:Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered 3Health News:Kellogg Company Announces Voluntary Nationwide Recall of Austin(R) and Keebler(R) Branded Peanut Butter Sandwich Crackers and Select Snack-Size Packs of Famous Amos(R) and Keebler(R) Soft Batch Peanut Butter Cookies Because of Possible Health Risk 2Health News:Kellogg Company Announces Voluntary Nationwide Recall of Austin(R) and Keebler(R) Branded Peanut Butter Sandwich Crackers and Select Snack-Size Packs of Famous Amos(R) and Keebler(R) Soft Batch Peanut Butter Cookies Because of Possible Health Risk 3Health News:Crdentia Corp. Finalizes Reverse Stock Split 2Health News:U.S. Department of Labor pays $4.5 billion in benefits under Energy Employees Occupational Illness Compensation Program Act 2Health News:African-Americans have worse prognosis at colorectal cancer diagnosis 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: